BRPI0818702A2 - Formulação farmacêutica de ácido clavulânico - Google Patents

Formulação farmacêutica de ácido clavulânico

Info

Publication number
BRPI0818702A2
BRPI0818702A2 BRPI0818702A BRPI0818702A2 BR PI0818702 A2 BRPI0818702 A2 BR PI0818702A2 BR PI0818702 A BRPI0818702 A BR PI0818702A BR PI0818702 A2 BRPI0818702 A2 BR PI0818702A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
clavulanic acid
clavulanic
acid
formulation
Prior art date
Application number
Other languages
English (en)
Inventor
Young Bok Lee
Deog Joong Kim
Chang Ho Ahn
Edward Carl Scholtz
Original Assignee
Rexahn Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Pharmaceuticals Inc filed Critical Rexahn Pharmaceuticals Inc
Publication of BRPI0818702A2 publication Critical patent/BRPI0818702A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0818702 2007-10-26 2008-10-24 Formulação farmacêutica de ácido clavulânico BRPI0818702A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99607907P 2007-10-26 2007-10-26
PCT/US2008/012126 WO2009055038A1 (en) 2007-10-26 2008-10-24 Pharmaceutical formulation of clavulanic acid

Publications (1)

Publication Number Publication Date
BRPI0818702A2 true BRPI0818702A2 (pt) 2015-04-22

Family

ID=40579869

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818702 BRPI0818702A2 (pt) 2007-10-26 2008-10-24 Formulação farmacêutica de ácido clavulânico

Country Status (11)

Country Link
US (1) US20090270358A1 (pt)
EP (1) EP2214680A4 (pt)
JP (1) JP2011500811A (pt)
KR (1) KR20100101574A (pt)
CN (1) CN101918004A (pt)
AU (1) AU2008317315A1 (pt)
BR (1) BRPI0818702A2 (pt)
CA (1) CA2703224A1 (pt)
IL (1) IL205313A0 (pt)
MX (1) MX2010004556A (pt)
WO (1) WO2009055038A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
KR20120012823A (ko) * 2009-04-29 2012-02-10 렉산 파마슈티컬스, 인코포레이티드 신경보호 및 퇴행성 신경 질환 치료용 클라블라네이트 제제
KR101628095B1 (ko) 2010-10-18 2016-06-08 현대자동차 주식회사 저압 ｅｇｒ시스템 제어장치 및 방법
CN102058584B (zh) * 2010-12-30 2012-01-25 石药集团河北中润制药有限公司 克拉维酸钾/微晶纤维素组合物的制备方法
DK2814849T3 (da) 2012-02-15 2020-03-09 Cydex Pharmaceuticals Inc Fremgangsmåde til fremstilling af cyclodextrin-derivater
NZ707323A (en) 2012-10-22 2018-11-30 Cydex Pharmaceuticals Inc Alkylated cyclodextrin compositions and processes for preparing and using the same
CN113842362A (zh) 2012-11-14 2021-12-28 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
EP3125873B1 (en) 2014-04-04 2020-06-03 Pharmaquest International Center, LLC Disintegrating monolithic modified release tablets containing quadri-layer extended release granules

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO984B1 (en) 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
NZ189022A (en) * 1977-12-08 1981-11-19 Beecham Group Ltd Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
NZ198241A (en) 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9405856D0 (en) * 1994-03-24 1994-05-11 Smithkline Beecham Plc Pharmaceutical formulation
GB9518917D0 (en) * 1995-09-15 1995-11-15 Smithkline Beecham Plc Compounds
IE990159A1 (en) * 1999-02-26 2000-09-20 Fuisz Internat Ltd Storage Stable Amoxycillin and Clavulanate Suspension Composition.
BR0013366A (pt) 1999-08-16 2002-07-23 Revaax Pharmaceuticals Llc Métodos para tratar um distúrbio comportamental, um paciente humano, doença de próstata, distúrbios de ansiedade e cognitivos em um paciente humano afligido com uma condição ou disposto ao desenvolvimento de uma condição distinguida pelo menos em parte pela concentração de glutamato extracelular anormal no cérebro ou em outro tecido nervoso, distúrbio comportamental nas espécies humana, canina, felina e equina e um paciente afligido com ou disposto a desenvolver uma doença compreendendo concentrações de glutamato anormalmente elevadas em tecido neuronal ou nìveis de naaladase elevados em tecido prostático e com esclerose múltipla e para realçar a função cognitiva, formulação farmacêutica e usos de um inibidor da atividade de peptidase de uma dipeptidase ácida ligada em alfa n-acetilada e de um composto de beta-lactama
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
US7166626B2 (en) * 2001-06-18 2007-01-23 Revaax Pharmaceuticals, Llc Therapeutic treatment for sexual dysfunction
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
PT1776109E (pt) * 2004-08-13 2009-03-25 Schering Plough Ltd Formulação farmacêutica que compreende um antibiótico, um triazol e um corticosteróide
DE102006007830A1 (de) * 2006-02-17 2007-08-30 Grünenthal GmbH Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure
ZA200807943B (en) * 2006-03-24 2009-11-25 Panacea Biotec Ltd Antibiotic compositions of modified release and process of production thereof
KR20120012823A (ko) * 2009-04-29 2012-02-10 렉산 파마슈티컬스, 인코포레이티드 신경보호 및 퇴행성 신경 질환 치료용 클라블라네이트 제제

Also Published As

Publication number Publication date
IL205313A0 (en) 2010-12-30
CN101918004A (zh) 2010-12-15
US20090270358A1 (en) 2009-10-29
JP2011500811A (ja) 2011-01-06
MX2010004556A (es) 2010-07-01
KR20100101574A (ko) 2010-09-17
CA2703224A1 (en) 2009-04-30
WO2009055038A1 (en) 2009-04-30
EP2214680A1 (en) 2010-08-11
EP2214680A4 (en) 2010-12-29
AU2008317315A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
DK2346495T4 (da) Farmaceutisk formulering 514
SMT201400069B (it) Formulazione farmaceutica
BRPI0813105A2 (pt) Derivado de sulfonamida de ácido malônico e uso faramacêutico do mesmo
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
BRPI0810439A2 (pt) Formulações farmacêuticas contendo derivados de ácido lipóico
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI0821474A2 (pt) formulação farmacêutica líquida estável
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada
IL211099A0 (en) Formulation for oral administration of proteins
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
BRPI0921654A2 (pt) formulação farmacêutica
GT201200303A (es) Formulaciones farmacéuticas
BRPI0818702A2 (pt) Formulação farmacêutica de ácido clavulânico
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
SMT201400053B (it) Forme farmaceutiche orali di bendamustina
BRPI0912428A2 (pt) formulação farmacêutica sólida de liberação retardada
DK2391351T3 (da) Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
DK2271618T3 (da) Farmaceutiske forbindelser
BRPI0912656A2 (pt) formulação farmacêutica sólida
UY33128A (es) Derivados de piridinona y composiciones farmacéuticas de los mismos
BRPI0912074A2 (pt) composto e composição farmacêutica
FI20080348A0 (fi) Uudenlainen farmaseuttinen formulaatio
IL213711A (en) Nano-phenofibrate preparation
BRPI0823402A2 (pt) Formulações farmacêuticas de olmesartan
BRPI0913709A2 (pt) "formulação farmacêutica"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.